Cardiac tolerance of moxifloxacin: clinical experience from a large observational French study in usual medical practice (IMMEDIAT study);Tolérance cardiaque de la moxifloxacine : expérience clinique issue d'une large étude observationnelle française en pratique médicale usuelle (étude IMMEDIAT)

Medecine et Maladies Infectieuses

Volumn 36, Issue 10, 2006, Pages 505-512

  Veyssier, P ^a   Voirot, P ^b   Begaud, B ^c   Funck Brentano, C ^d  

^a CHR   (France)

^b Service de Cardiologie   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d HÔPITAL SAINT ANTOINE   (France)

Author keywords

Cardiac tolerance; Moxifloxacin; QT prolongation; Torsade de pointes; Usual medical practice

Indexed keywords

AMIODARONE; AMLODIPINE; ATORVASTATIN; DILTIAZEM; FENOFIBRATE; FLECAINIDE ACETATE; FUROSEMIDE; GLYCERYL TRINITRATE; IZILOX; MOXIFLOXACIN; PRAVASTATIN; SIMVASTATIN; VERAPAMIL;

ABDOMINAL PAIN; ADULT; ANGIONEUROTIC EDEMA; BALANCE DISORDER; BRADYCARDIA; BRONCHOSPASM; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COMA; CONFUSION; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DIARRHEA; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; ERYTHEMA; FEMALE; FRANCE; GASTROINTESTINAL SYMPTOM; HEART; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART INFARCTION; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPESTHESIA; HYPOKINESIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDICAL PRACTICE; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; OBSERVATIONAL STUDY; PALLOR; PATIENT ASSESSMENT; PATIENT MONITORING; PATIENT SELECTION; PROSPECTIVE STUDY; QT PROLONGATION; RESPIRATORY TRACT INFECTION; REVIEW; SAMPLE; SIDE EFFECT; SINUS BRADYCARDIA; SOMNOLENCE; SUPRAVENTRICULAR TACHYCARDIA; SYNCOPE; TACHYCARDIA; TENDINITIS; TENDON DISEASE; THORAX DISEASE; TINNITUS; TORSADE DES POINTES; TREATMENT DURATION; URTICARIA; VERTIGO; VISUAL DISORDER; VOMITING;

EID: 33751520003     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2006.09.001     Document Type: Review

References (35)

1. Keating G.M., and Scott L.J. Moxifloxacin. A review of its use in the management of bacterial infections. Drugs 64 (2004) 2347-2377
2. Bayer Pharma. Résumé des caractéristiques du produit (RCP) Moxifloxacine, vidal 2006
3. Owens R.C. QT prolongation with antimicrobial agents. Understanding the significance. Drugs 64 (2004) 1091-1124
4. Rubinstein E., and Camm J. Cardiotoxicity of fluoroquinolones. J. Antimicrob. Chemother. 49 (2002) 593-596
5. Ball P., Stahlmann R., Kubin R., Choudhri S., and Owens R. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin. Ther. 26 (2004) 940-950
6. EMEA. The Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. ICH E14 (2004, 10 June) (17 pages)
7. Gowda R.M., Khan I.A., Wilbur S.L., Vasavada B.C., and Sacchi T.J. Torsade de pointes: the clinical considerations. Int. J. Cardiol. 96 (2004) 1-6
8. Crough M.A., Limon L., and Cassano A.T. Clinical relevance and management of drug-related QT interval prolongation. Pharmacother. 23 (2003) 881-908
9. Iannini P.B. Fluoroquinolone toxicity: a review of class-and agent-specific adverse effects. Drugs Benefit Trends. suppl. (2004) 34-41
10. Montanez A., Rushin J.N., Hebert P.R., Lamas G.A., and Hennekens C.H. Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population. A review and qualitative overview of prospective cohort studies. Arch. Intern. Med. 164 (2004) 943-948
11. De Bruin M.L., Pettersson M., Meyboom R.H., Hoes A.W., and Leufkens H.G. Anti HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur. Heart J. 6 (2005) 590-597
12. Straus S.M., Sturkenboom M.C., Bleumink G.S., Dieleman J.P., Van der Lei J., de Graeff P.A., et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur. Heart J. 11 26 (2005) 2007-2012
13. Ray W.A., Murray K.T., Meredith S., Narasimhulu S.S., Hall K., and Stein C.M. Oral erythromycin and the risk of sudden death from cardiac causes. N. Engl. J. Med. 351 (2004) 1089-1096
14. Demolis J.L., Kubitza D., Tennezé L., and Funck-Brentano C. Effect of a single oral dose of moxifloxacin (400mg and 800mg) on ventricular repolarization in healthy subjects. Clin. Pharmacol. Ther. 68 (2000) 658-666
15. Iannini P.B. Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval. Expert Opin. Drug Saf. 1 (2002) 121-128
16. Henry D.C., Moller D.J., Adelglass J., Scheld W.M., Jablonski C.K., Zhang H., et al., Sparfloxacin Multicenter AMS Study Group. Comparison of sparfloxacin and clarithromycin in the treatment of acute bacterial maxillary sinusitis. Clin. Ther. 21 (1999) 340-352
17. Ramirez J., Unowsky J., Talbot G.H., Zhang H., and Townsend L. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. Clin. Ther. 21 (1999) 103-117
18. Ross D. Telithromycin (KETEK™): General safety profile. Anti-infective Drugs Advisory Committee April 26, 2001. http://www.fda.gov/ohrms/dockets/ac/01/slides/3746s_05_Ross/sld024.htm.
19. Iannini P.B., Kramer H., Circiumaru I., Byazrova E., and Doddamani S. QTc prolongation associated with levofloxacin (2000), 40th ICAAC, Toronto, Canada (Abstract 882)
20. Owens R.C. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes. Pharmacother. 21 (2001) 301-319
21. Smith K., and Lomaestro B.M. What role do fluoroquinolone antimicrobial agents play in cardiac dysfunction and altered glycemic control?. J. Pharmacol. Pract. 16 (2003) 349-360
22. Fish D.N. Fluoroquinolone adverse effects and drug interaction. Pharmacother. 21 (2001) 253S-272S
23. Benton R.E., Honig P.K., Zamani K., Cantilena L.R., and Woosley R.L. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin. Pharmacol. Ther. 59 (1996) 383-388
24. Woosley R.L., Chen Y., Freiman J.P., and Gillis R.A. Mechanism of the cardiotoxic actions of terfenadine. JAMA 269 (1993) 1532-1536
25. Faisch G.A., Morganroth J., Whitehouse A.B., Brar J.S., Arcuri P., Kowalsky S.F., et al. Clinical experience with moxifloxacin in patients with respiratory tract infections. Ann. Pharmacother. 38 (2004) 749-754
26. Landen H., and Bauer T. Efficacy, onset of action and tolerability of moxifloxacin in patients with community-acquired pneumonia. Clin. Drug Invest. 21 (2001) 801-811
27. Barth J., and Landen H. Efficacy and tolerability of moxifloxacin in 2338 ptients with acute exacerbation of chronic bronchitis. Clin. Drug Invest. 23 (2003) 1-10
28. Koch H., Landen H., and Stauch K. Daily-practice treatment of acute exacerbations of chronic bronchitis with moxifloxacin in a large cohort in Germany. Clin. Drug Invest. 24 (2004) 449-455
29. Amankwa K., Krishnan S.C., and Tisdale J.E. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors. Clin. Pharmacol. Ther. 75 (2004) 242-247
30. Roden D.M. Drug-induced prolongation of the QT interval. N. Engl. J. Med. 350 (2004) 1013-1022
31. Shah R.R. Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity. Fundament. Clin. Pharmacol. 16 (2002) 147-156
32. Kando J.C., Yonkers K., and Cole J.O. Gender as a risk factor for adverse events to medications. Drugs 50 (1995) 1-6
33. Onder G., Pedone C., Landi F., Cesari M., Vedova C.D., Bernabei R., et al. Adverse drug reactions as cause of hospital admissions : results from the italian Group of Pharmacoepidemiology in the elderly (GIFA). Geriatr. Soc. 50 (2002) 1962-1968
34. Fattinger K., Roos M., Vergeres P., Holenstein C., Kind B., Masche U., et al. Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine. Br. J. Clin. Pharmacol. 49 (2000) 158-167
35. Montastruc J.L., Lapeyre-Mestre M., Bagheri H., and Fooladi A. Gender differences in adverse drug reactions : analysis of spontaneous reports to a Regional Pharmacovigilance Centre in France. Fundam. Clin. Pharmacol. 16 5 (2002) 343-346